Table 1.
Baseline Characteristics
| Patient characteristics | n = 43 |
|---|---|
| Age (years) at treatment start, median (range) | 57 (21–81) |
| Sex, n (%) | |
| Male | 22 (51) |
| Female | 21 (49) |
| Ethnicity, n (%) | |
| Caucasian | 36 (84) |
| Black | 3 (6) |
| Hispanic | 2 (5) |
| Asian | 2 (5) |
| Type of cancer, n (%) | |
| Melanoma | 10 (23) |
| Renal-cell carcinoma | 9 (21) |
| Lung cancer | 8 (19) |
| Urothelial carcinoma | 5 (12) |
| Colon cancer | 4 (9) |
| Glioblastoma multiforme | 3 (7) |
| Ovarian cancer | 2 (4.5) |
| Othersa | 2 (4.5) |
| Type of immunotherapy, n (%) | |
| Ipilimumab + nivolumab | 17 (39.5) |
| Nivolumab | 14 (32.5) |
| Pembrolizumab | 9 (21) |
| Durvalumab + tremelimumab | 2 (4.65) |
| Tremelimumab | 1 (2.35) |
| Follow-up time (months), median (range) | 17.63 (1–41.25) |
a
Other cancer diagnoses included pancreatic adenocarcinoma in one patient and non-Hodgkin's lymphoma in one patient.